Roche's Tecentriq Gets The Double At The EU CHMP
Executive Summary
Roche's checkpoint inhibitor Tecentriq clears the EU approval hurdle in locally advanced or metastatic urothelial carcinoma and locally advanced or metastatic non-small cell lung cancer.